Review Article

Current trends for biosimilars in the Latin American market

Published in: Volume 9 / Year 2020 / Issue 2
Author(s): , , , , , , , ,
Page: 64-74

Author byline as per print journal: Esteban Ortiz-Prado1,2, MD, MSc, MPH, PhD; Jorge Ponce-Zea3, MSc; Jorge E Vasconez1, MD; Diana Castillo,1, MD; Diana C Checa-Jaramilloz1, MD; Nathalia Rodrí­guez-Burneo1, MD; Felipe… Read More »

Global challenges in the manufacture, regulation and international harmonization of GMP and quality standards for biopharmaceuticals

Published in: Volume 9 / Year 2020 / Issue 2
Author(s): , ,
Page: 52-63

Author byline as per print journal: Adjunct Associate Professor Sia Chong Hock, BSc (Pharm), MSc; Associate Professor Sia Ming Kian, BSc (Pharm) (Hons); Chan Lai Wah, BSc (Pharm) (Hons), PhD… Read More »

An ever-evolving landscape: an update on the rapidly changing regulation and reimbursement of biosimilars in Canada

Published in: Volume 8 / Year 2019 / Issue 3
Author(s): , , , ,
Page: 107-18

Author byline as per print journal: Eric CK Siu1,4, MSc, PhD; Anne Tomalin2,4, BA, BSc; Kevin West3,4, BA; Sandra Anderson4, BA, MBA; George Wyatt1,4, BSc, MBA Abstract: Since the introduction… Read More »

Are there biosimilar orphan drugs for Gaucher disease? An overview in Mexico

Published in: Volume 8 / Year 2019 / Issue 2
Author(s): , , , , , , , , , ,
Page: 71-5

Author byline as per print journal: G Castañeda-Hernández, PhD; L Carbajal-Rodríguez, MD; M Cerón-Rodríguez, MD; Professor LC Correa-González, MD; A Esquivel-Aguilar, PhD; SJ Franco-Ornelas, MD; JE García Ortiz, PhD; CM… Read More »

The need for distinct nomenclature for originator and biosimilar products

Published in: Volume 7 / Year 2018 / Issue 4
Author(s): , , ,
Page: 152-7

Author byline as per print journal: Michael Sarshad, BSc, MBA; Rosanne Campbell, BComm, PGdip, MSc; Peter J Pitts, BA; Jacqueline anderpuye- Orgle, MSc, PhD Abstract: As the number of biosimilar… Read More »

Protein heterogeneity and the immunogenicity of biotherapeutics

Published in: Volume 7 / Year 2018 / Issue 2
Author(s):
Page: 63-9

Abstract: High resolution analytical techniques reveal structural micro-heterogeneity within endogenous proteins, however, they are ‘seen’ as ‘self’ molecules by the immune system and immunological tolerance is established. In contrast the… Read More »

The impact of religion on human embryonic stem cell regulations: comparison between the UK, Germany and the US

Published in: Volume 7 / Year 2018 / Issue 1
Author(s): ,
Page: 22-5

Author byline as per print journal: Hajaj M Alhomaidan; Ali M Alhomaidan, PhD Abstract: This paper describes the differences in human embryonic stem cell regulations in several Christian countries across… Read More »

Biosimilar infliximab introduction into the gastroenterology care pathway in a large acute Irish teaching hospital: a story behind the evidence

Published in: Volume 7 / Year 2018 / Issue 1
Author(s): , , , , ,
Page: 14-21

Author byline as per print journal: Gary L O’Brien1, BPharm, MPharm; Donal Carroll2, BSc (Hon) Pharmacy; Mark Mulcahy3, BComm, MSc, PhD; Valerie Walshe4, BA, MA, PhD; Professor Garry Courtney2, MB, FRCPI;… Read More »

Major lessons learned from Zarxio’s US launch: the start of a biosimilar revolution

Published in: Volume 6 / Year 2017 / Issue 4
Author(s):
Page: 165-73

Introduction: Launched in 2015, Zarxio™ (filgrastim-sndz) was the first biosimilar to gain US Food and Drug Administration (FDA) approval. In contrast, the first biosimilar was launched in Europe in 2006.… Read More »

Biosimilars in Italy: what do real-world data reveal?

Published in: Volume 6 / Year 2017 / Issue 3
Author(s): , , ,
Page: 114-9

Author byline as per print journal: Assistant Professor Gianluca Trifirò, MD, PhD; Ylenia Ingrasciotta, MSc; Ilaria Marcianò, MSc; Armando Genazzani, DPhil, MD Abstract: This paper aims to provide an overview of… Read More »

Page 1 of 5 1 2 3 4 5 Next »
Go Back Print